Ji Xing buys Biogen’s acute ischemic stroke drug; Exelixis/BioInvent partnership ends; ClinChoice's deal in SEA

12 Jan 2024
endpts.com
License out/inAcquisitionImmunotherapyDrug Approval
Ji Xing acquires Biogen’s experimental therapy for acute ischemic stroke: The Shanghai-based biopharma did not disclose the financial terms of the deal. Back in 2018, Biogen licensed the drug for $4 million upfront, with up to $335 million in milestones, before fully acquiring the asset in 2021. — Jaimy Lee
BioInvent gets back rights to immuno-oncology targets: Exelixis is returning the full rights to the Swedish biotech’s antibodies after announcing a restructuring earlier this week. BioInvent said the transition is expected to wrap up in the next 90 days. — Jaimy Lee
Ji Xing buys Biogen’s acute ischemic stroke drug; Exelixis/BioInvent partnership ends; ClinChoice's deal in SEA
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.